Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):967–971. doi: 10.1038/bjc.1994.187

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group.

A Riviere 1
PMCID: PMC1968916  PMID: 8180032

Abstract

The efficacy and safety of three different doses of granisetron (2 micrograms kg-1, group A; 10 micrograms kg-1, group B; 40 micrograms kg-1, group C) were compared in a randomised, double-blind study of 157 patients due to receive high-dose cisplatin therapy (mean dose > 97 mg m-2). In each group, up to two 3 mg rescue doses of granisetron were allowed if more than mild nausea or vomiting occurred. In group A 30.8%, in group B 61.5% and in group C 67.9% of patients were complete responders (i.e. no vomiting or nothing worse than mild nausea) during the first 24 h. These differences are significant between groups A and B, and A and C. There were no statistically significant differences in any efficacy variable between the 10 micrograms kg-1 and 40 micrograms kg-1 groups, although in each case the trend favoured the higher dose. Additional rescue doses resulted in resolved or improved symptoms in 95.3% for the first rescue dose and 93.3% for the second. Over the 7 days of the study, 82.7%, 82.7% and 86.8% of patients in groups A, B and C respectively were treated with granisetron alone. Headache was the most common side-effect, reported by 9.6% of patients; the majority of headaches were mild. There was no difference between the treatment groups regarding the adverse event rate. We concluded that prophylactic doses of 10 or 40 micrograms kg-1 lead to a safe and satisfactory degree of control of nausea and vomiting induced by high-dose cisplatin.

Full text

PDF
967

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blower P. R. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer. 1990;26 (Suppl 1):S8–11. [PubMed] [Google Scholar]
  2. Borison H. L., McCarthy L. E. Neuropharmacology of chemotherapy-induced emesis. Drugs. 1983 Feb;25 (Suppl 1):8–17. doi: 10.2165/00003495-198300251-00003. [DOI] [PubMed] [Google Scholar]
  3. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer. 1990;26 (Suppl 1):S33–S36. [PubMed] [Google Scholar]
  4. Coates A., Abraham S., Kaye S. B., Sowerbutts T., Frewin C., Fox R. M., Tattersall M. H. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983 Feb;19(2):203–208. doi: 10.1016/0277-5379(83)90418-2. [DOI] [PubMed] [Google Scholar]
  5. Cupissol D. R., Serrou B., Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer. 1990;26 (Suppl 1):S23–S27. [PubMed] [Google Scholar]
  6. Gralla R. J., Itri L. M., Pisko S. E., Squillante A. E., Kelsen D. P., Braun D. W., Jr, Bordin L. A., Braun T. J., Young C. W. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981 Oct 15;305(16):905–909. doi: 10.1056/NEJM198110153051601. [DOI] [PubMed] [Google Scholar]
  7. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., Groshen S. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer. 1987 Dec 1;60(11):2816–2822. doi: 10.1002/1097-0142(19871201)60:11<2816::aid-cncr2820601137>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  8. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., O'Connell J. P., Wertheim M. S., Kelsen D. P. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985 Oct;3(10):1379–1384. doi: 10.1200/JCO.1985.3.10.1379. [DOI] [PubMed] [Google Scholar]
  9. Laszlo J., Lucas V. S., Jr Emesis as a critical problem in chemotherapy. N Engl J Med. 1981 Oct 15;305(16):948–949. doi: 10.1056/NEJM198110153051609. [DOI] [PubMed] [Google Scholar]
  10. Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Eur J Cancer. 1990;26 (Suppl 1):S28–S32. [PubMed] [Google Scholar]
  11. Roila F., Boschetti E., Tonato M., Basurto C., Bracarda S., Picciafuoco M., Patoia L., Santi E., Penza O., Ballatori E. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 1991 Jun;14(3):238–242. doi: 10.1097/00000421-199106000-00010. [DOI] [PubMed] [Google Scholar]
  12. Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. Eur J Cancer. 1990;26 (Suppl 1):S15–S19. [PubMed] [Google Scholar]
  13. Strain J. E. The American Academy of Pediatrics comments on the "Baby Doe II" regulations. N Engl J Med. 1983 Aug 18;309(7):443–444. doi: 10.1056/NEJM198308183090728. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES